替比夫定在阻断乙肝病毒母婴传播中的应用效果分析

Analysis of Application Effect of Sebivo in Obstruction of HBV Mother-to-Fetus Transmission

分析替比夫定在阻断乙肝病毒母婴传播中的应用效果。选择60位孕妇作为实验对象,将其分为实验组与对照组。实验组15例,对照组45例。实验组对乙肝病毒的脱氧核糖核酸(HBV-DNA)即乙肝病毒基因超过或者等于10×5 e拷贝/ml的怀孕妇女开展药物治疗。在妊娠期满28周后使用替比夫定,剂量为600 mg,每天一次。药物使用期间,严格监测肌酸激酶(CK)的变化。将不能接受抗病毒药物治疗的孕妇作为对照组。两组孕妇在产下新生儿后的6 h内,对新生儿采血,检测HBsAg、HBV-DNA指标,并比较两组新生儿的阳性率。实验组孕妇,生产之前HBV-DNA与最初检测的数值相比,下降指标显著小于对照组。实验组新生儿的HBsAg、HBV-DNA阳性率显著优于对照组。替比夫定在阻断乙肝病毒母婴传播中的应用效果非常理想,可降低并发症的发病率。需要重点注意的问题是在使用抗病毒药物期间,要关注CK的变化,观察孕妇对抗病毒药物产生的不良反应。

The research analyzes the application effect of Sebivo in obstruction of HBV mother-to-fetus transmission.60 pregnant women are selected as the experimental objects,and they are divided into experimental group and control group.There are 15 women in experimental group,and 45 women in control group.Medicine treatment is done on pregnant women whose HBV virogene in the experimental group is or above 10×5 e copies/ml.After 28 weeks gestation period,and they are treated with 600 mg Sebivo once a day.During medicine use period,CK change is strictly monitored.Pregnant women who do not receive antiviral drug treatment are regarded as the control group.6 h after birth,through blood sampling,HBsAg and HBV-DNA indexes are tested.Positive rates of newborns of two groups are compared.The decrease index in experimental group is significantly less than control group.The positive rates of HBsAg and HBV-DNA of the newborns in the experimental group are significantly better than control group.The application result of Sebivo in obstruction of HBV mother-to-fetus transmission is ideal.It can reduce the morbidity rate.We should pay attention to the CK change and observe the adverse the reaction of antiviral drug of pregnant women when they use antiviral drug.